At the 61st ASH Annual Meeting & Exposition, Louis Williams, NYU Langone Medical Center, provides a snapshot of his recent article with Oncology & Hematology (US) exploring genetic segmentation and targeted therapeutics for multiple myeloma.
1. How has increased understanding of the molecular biology of multiple myeloma impacted on risk stratification of patients? (0:05)
2. Could you tell us a little about B-cell maturation antigen targeted therapies? (1:02)
3. What other emerging targeted therapies seem promising? (2:34)
4. With so many new therapies available, how can we best incorporate them into the treatment paradigm? (3:56)
5. What other pathways are potential therapeutic targets? (5:28)
Louis Williams has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial
We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!